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Aims Plasma levels of apolipoprotein B (apoB), the main surface protein on LDL particles, and LDL-C, the amount of
cholesterol in those particles, are closely correlated and, considered separately, are positive risk factors. Plasma
levels of apolipoprotein A1, the main surface protein on HDL particles, and HDL-C, the amount of cholesterol in
those particles, are also closely correlated with each other and, considered separately, are negative risk factors.
The interdependence of these four risk factors is unclear.
Methods
and results
Case–control study among 3510 acute myocardial infarction patients (without prior vascular disease, diabetes, or
statin use) in UK hospitals and 9805 controls. Relative risks (age, sex, smoking, and obesity-adjusted) were more
strongly related to apoB than to LDL-C and, given apoB, more strongly negatively related to apoA1 than to HDL-C.
The ratio apoB/apoA1 was uncorrelated with time since symptom onset in cases, was reproducible in samples collected
a few years apart in controls (correlation 0.81), and encapsulated almost all the predictive power of these four measure-
ments. Its effect was continuous, substantial throughout the UK normal range [relative risk, top vs. bottom decile of this
ratio, 7.3 (95% CI 5.8–9.2)] and varied little with age. The ratio apoB/apoA1 was substantially more informative about
risk (x1
2 ¼ 550) than were commonly used measures such as LDL-C/HDL-C, total/HDL cholesterol, non-HDL choles-
terol, and total cholesterol (x1
2 ¼ 407, 334, 204, and 105, respectively). Given apoB and apoA1, the relationship with
risk of LDL-C was reversed, and this reversal was strengthened by appropriate allowance for random measurement
errors in two correlated variables. Given usual apoB, lower LDL-C (consistent with smaller LDL particles) was associ-
ated with higher risk (P , 0.0001). During the ﬁrst 8 h after symptom onset HDL-C increased by about 10%, precluding
reliable assessment of the joint relationship of apoA1 and pre-onset HDL-C with risk in such retrospective case–
control studies.
Conclusion Apolipoprotein ratios are more informative about risk than lipid fractions are. This suggests that, among lipoprotein
particles of a particular type (LDL or HDL), some smaller and larger subtypes differ in their effects on risk. Direct
measurements of even more speciﬁc subtypes of lipoprotein particles may be even more informative about risk.
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Some low-density lipoprotein (LDL) particles can damage coron-
ary arteries, and some high-density lipoprotein (HDL) particles
can help limit the damage. Hence, plasma levels of LDL cholesterol
(LDL-C) and HDL cholesterol (HDL-C)—the total amounts of
cholesterol being carried in LDL and in HDL particles—are,
respectively, positive and negative risk factors for coronary heart
disease, as are plasma levels of apolipoproteins B (apoB) and A1
(apoA1), which are, respectively, the main surface proteins on
LDL and on HDL particles. Consideration of all four factors
could improve risk prediction and understanding.
Plasma LDL and HDL particles have different origins and func-
tions. Big, triglyceride-laden precursors of LDL particles enter
the circulation as very-low-density lipoprotein particles and
deliver their contents to peripheral tissues, rapidly shrinking into
intermediate-density lipoprotein particles which, unless cleared,
shrink to LDL particles. Each LDL precursor particle has exactly
one molecule of apoB on its surface, which remains there during
shrinkage to an LDL particle.
1 Generally, more than 90% of
plasma apoB is on LDL particles (the remainder being on their pre-
cursors) and most plasma cholesterol is in LDL particles. Larger
LDL particles carry about 2500 molecules of cholesterol, but
smaller, denser LDL particles might carry only about 2000.
2
Some studies have suggested that small, dense LDL particles may
be particularly hazardous,
3 although other studies have not.
4,5
The precursors of HDL particles are initially small (containing no
cholesterol) and then repeatedly gain cholesterol and lose some
cholesterol, but even the largest HDL particles are much smaller
and denser than any LDL particles. The HDL particles each have
a few (e.g. two or three) molecules of apoA1 on their surface
and account for nearly all plasma apoA1.
6 They vary considerably
in size, cholesterol content, and probably in biological activity. Col-
lectively, HDL particles (and their precursors) can reverse-
transport excess cholesterol from peripheral tissues, such as
artery walls. Small HDL particles, which are more numerous, typi-
cally carry only two molecules of apoA1 and a few dozen choles-
terol molecules, while large ones might carry three molecules of
apoA1 and over 100 cholesterol molecules. Such HDL particles
can transfer some of their load of cholesterol to the triglyceride-
rich precursors of LDL particles, and high triglyceride levels are
associated with low HDL-C levels. The independent relevance of
HDL-C (or of particular types of HDL particle) to risk is, therefore,
best assessed by analyses that are adjusted for any effects on risk of
LDL particles or their precursors.
As the ratios of cholesterol to apolipoprotein within LDL and
within HDL particles can vary, the positive associations of apoB
and of LDL-C with risk may differ, as may the negative associations
of apoA1 and of HDL-C with risk. It has been reported that apoB
and apoA1 are even stronger correlates of risk than LDL-C and
HDL-C are,
7,8 but no study with a large number of cases with
disease has involved direct measurement of all four factors.
The present study, with direct measurements of LDL-C, HDL-C,
apoB, and apoA1, investigates risk associations in 3510 cases
of non-fatal acute myocardial infarction (MI) and 9805 controls,
all without any previous history of vascular disease or diabetes
(and hence little use of lipid-altering drugs).
Methods
Design, setting, and participants
The study design is described elsewhere, and in Supplementary
material online, Appendix.
9–15Potential cases were acute MI survivors
aged 30–79 in 1989–90 in the UK who had given blood on entry to
hospital (mean 6 h from pain onset). Controls were ﬁrst degree rela-
tives of potential cases or spouses of such relatives. Whole blood
spent a mean of 1.8 days in the post before being separated in
Oxford (Supplementary material online, Tables A1–A3). This report
is of the 3510 cases and 9805 controls with valid assay results for
apoB, apoA1, LDL-C, HDL-C, and total cholesterol, and with no
prior vascular disease or diabetes (Table 1; Supplementary material
online, Tables A4–A5). The apoB, apoA1, LDL-C, and total cholesterol
levels were not associated with hours from onset of pain in cases;
HDL-C increased with hours from pain onset, however (Supplemen-
tary material online, Figure A1), and this was corrected for.
Statistical methods
For details see Supplementary material online, Appendix.
Relative risks and ﬂoating absolute risks
Relative risks of MI (RRs; case vs. control odds ratios) were estimated
by logistic regression using SAS
16,17 adjusted for age, sex, current
smoking, and body mass index (BMI). Plots of risk use groupings
based on decile boundaries (among cases) of similarly adjusted
analyte values. Relative risks are presented as ‘ﬂoating absolute
risks’
18 with 95% conﬁdence intervals (CIs), and P-values are
two-sided.
................... ...................
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Table 1 Lipid-related factors in cases and controls:
means and coefﬁcients of variation of measured values,
calculated after adjustment for age, sex, smoking, and
body mass index
Characteristic Cases
(3510)
Controls
(9805)
Mean CV, % Mean CV, %
Lipid-related measurements
LDL-C (mmol/L) 3.636 25 3.362 23
ApoB (g/L) 1.166 21 1.064 20
HDL-C (mmol/L) 1.122 22 1.242 23
ApoA1 (g/L) 1.375 15 1.449 15
Total cholesterol (mmol/L) 5.864 19 5.596 17
Ratios of measurements
LDL-C/apoB 3.118 13 3.162 13
HDL-C/apoA1 0.814 16 0.853 16
LDL-C/HDL-C 3.411 32 2.881 30
Total cholesterol/HDL-C 5.512 30 4.786 26
ApoB/apoA1 0.863 23 0.749 22
Molecular weights: cholesterol (unesteriﬁed) 387 Da, apoB 513 kDa, and apoA1
28 kDa (so, mg/dL cholesterol= mmol/L   38.7, mmol/L apoB =g/L4513, and
mmol/L apoA1= g/L428). To obtain molar ratios, multiply LDL-C/apoB by 513,
multiply HDL-C/apoA1 by 28, and multiply apoB/apoA1 by 28/513 (e.g. among
controls the molar ratio is 1625 for LDL-C/apoB, 24 for HDL-C/apoA1, and 0.04
for apoB/apoA1). CV, coefﬁcient of variation of measured values.
S. Parish et al. 2138Measured values and usual values
Logistic regression yields b, the log of the relative risk associated with a
unit difference in the measured value of a lipid-related factor. Because
of random measurement error (which includes any within-person ﬂuc-
tuation), this regression coefﬁcient tends to underestimate the real
importance of a unit difference in the ‘usual’ (i.e. medium-term
average) level of that factor.
19 This ‘regression dilution’ bias is cor-
rected for by dividing b by r, the self-correlation between measure-
ments of that factor in blood samples taken 2–3 years apart from
1042 controls. Likewise, when the measured values of a lipid-related
factor are divided into several groups, the mean usual value in each
group is taken to differ from that in the central group by r times the
corresponding difference in the measured values. (Simultaneous cor-
rection for measurement error in two positively correlated factors is
described in the Results.)
Relative risk per two standard deviation difference
in the usual value
To facilitate direct comparison of the strengths of different associ-
ations, for each factor relative risks are presented for a 2SD difference
of that factor, where SD is deﬁned as the standard deviation of the
usual value in cases (given age, sex, smoking and BMI). Plots of risk
Figure 1 Relative risk of myocardial infarction at different usual levels of LDL-C, HDL-C, apoB, apoA1, their ratio (apoB/apoA1) and total
cholesterol based on 3510 cases vs. 9805 controls, all without prior vascular disease. Relative risks and 95% CIs, adjusted for age, sex,
smoking, and body mass index, are plotted against the mean usual value (i.e. the medium-term average value after allowance for measurement
error). The seven groups are based on deciles or, for the middle three groups, quintiles of the values among cases. Horizontal scales are deﬁned
similarly in all graphs, with the marked points 2SD above and below the median (in the middle group) at the same positions. MI, myocardial
infarction; RR, relative risk; SD, standard deviation of usual value in cases.
Effects of ApoB, ApoA1, LDL-C, and HDL-C on risk 2139(Figure 1) have been scaled so that the same physical distance horizon-
tally represents 2SD for each factor. (Note that the difference
between the mean values in the top and bottom thirds of a normal dis-
tribution is 2.2 standard deviations.)
Magnitude of improvement in risk prediction
Twice the increase in the log-likelihood on the addition of extra terms
gives a x
2 statistic, with degrees of freedom equal to the number of
extra terms added. This provides not only a signiﬁcance test for the
improvement in ﬁt from including the added terms but also, more
importantly, a quantitative measure of the extent to which the
added terms improve risk prediction. (The x
2 improvement on
jointly ﬁtting several independent risk factors is approximately the
sum of the x
2 improvements on ﬁtting each separately.)
Robustness
Further analyses, and sensitivity analyses of the robustness of the main
ﬁndings, are in Supplementary material online, Tables A6–A9.
Results
Relationship of risk to usual values
of single factors
Table 1 gives the means in cases and controls of the ﬁve directly
measured biochemistries and selected ratios of them. Figure 1
shows MI risk vs. usual values for six lipid-related factors, with
ﬁtted lines from Table 2. The association was strongly positive
for LDL-C and apoB, strongly negative for HDL-C and apoA1,
and even more strongly positive for the ratio apoB/apoA1.
The relative risk comparing the top vs. bottom decile of this
ratio was 7.33 (95% CI 5.81–9.24, allowing for the ﬂoated
variances in both groups). Total cholesterol was more weakly
related to risk.
Table 2 gives relative risks per 2SD difference for several
common measures. The ratio apoB/apoA1 was a substantially
stronger risk factor than the ratio LDL-C/HDL-C (x1
2 = 549.6
and 406.8, respectively) or any other measure. If total and
HDL cholesterol were the only measurements used, then
for risk prediction the ratio total/HDL cholesterol was much
better than non-HDL cholesterol (x1
2= 334.5 and 204.3,
respectively).
Figure 2 shows the effects of age on the relative risks. For apoB,
apoA1, and particularly, apoB/apoA1, any attenuation appeared to
be small in proportion to the effect in middle age. So, even at
ages 70–79, a 2SD higher apoB/apoA1 ratio was associated with
a highly signiﬁcant (P , 0.00001) relative risk of 3.13. For total
cholesterol, however, there appeared to be substantial attenuation
with age (as in some other studies
20–23). Relative risks within other
subgroups (Figure 3) showed no clear heterogeneity of effect with
respect to sex, smoking, or BMI.
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Table 2 Relative risks associated with differences of 2SD in the usual values of various lipid-related factors
Lipid-related factor r
a Mean
a 2SD
b RRassociatedwith a differenceof
2SD in usual value
b
RR (95% CI) x
2
LDL-related factors
LDL-C (mmol/L) 0.730 3.64 1.526 2.21 (1.96–2.48) 175.2
ApoB (g/L) 0.733 1.17 0.412 2.66 (2.37–2.99) 279.7
HDL-related factors
HDL-C (mmol/L) 0.768 1.12 0.430 2.39 (2.03–2.81) 290.6
ApoA1 (g/L) 0.680 1.38 0.330 2.33 (2.07–2.62) 212.9
HDL-related factors, adjusted for apoB
HDL-C (mmol/L) 2.06 (1.76–2.44) 187.7
ApoA1 (g/L) 2.71 (2.40–3.06) 278.5
Total and non-HDL cholesterol
Total cholesterol (mmol/L) 0.757 5.86 1.890 1.82 (1.62–2.04) 104.9
Non-HDL cholesterol (mmol/L) 0.771 4.74 1.756 2.10 (1.89–2.33) 204.3
Ratios
LDL-C/apoB 0.327 3.12 0.466 0.78 (0.66–0.92) 8.7
HDL-C/apoA1 0.531 0.81 0.194 1.94 (1.52–2.47) 106.9
Total/HDL cholesterol 0.717 5.51 2.766 3.10 (2.63–3.64) 334.5
LDL-C/HDL-C 0.741 3.41 1.834 3.26 (2.82–3.78) 406.8
ApoB/apoA1 0.812 0.86 0.358 3.80 (3.38–4.27) 549.6
aThe self correlation, r, is the correlation coefﬁcient between the measured values in samples taken 2–3 years apart from 1042 controls. The standard error of each r can be
estimated as (1 2 r
2)/
p
1042, which is between 0.01 and 0.03.
bSD, standard deviation of the usual value in cases; RR, relative risk.
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of different factors
Correlations between measurements some time apart (Table 3,
right), which avoid artefactual same-sample effects, showed that
apoB and LDL-C were not just two equivalent ways of assaying
LDL particles, nor were apoA1 and HDL-C two equivalent
ways of assaying HDL particles. For, there was a highly signiﬁ-
cantly negative correlation between apoB and HDL-C
(c ¼ 20.20, SE 0.02), but not between LDL-C and apoA1 (c ¼
0.00, SE 0.02). Moreover, the ratios LDL-C/apoB and HDL-C/
apoA1 were positively correlated with each other (c ¼ 0.17, SE
0.02), showing that both were informative. These correlations
have been independently replicated
24 (Supplementary material
online, Table A6).
The negative correlation between apoB and HDL-C corre-
sponds to the correlations of triglycerides with high apoB and
low HDL-C (and, particularly, with a low ratio of HDL-C to
apoA1; Supplementary material online, Table A7).
Joint relationship of risk to measured
values of more than one factor
Table 4 (and Supplementary material online, Table A8) gives the
improvements in ﬁt when one or several extra terms were
added into the logistic regression. The x
2 for adding apoB alone
(279.7) was virtually as great as that for adding both LDL-related
factors, apoB and LDL-C (281.3: Table 4). Indeed, given the
measured value of apoB, that of LDL-C was slightly negatively
related to risk. The x
2 for adding LDL-C alone was, in contrast,
only 175.2, giving a x
2 of 106.1 (281.3–175.2; P , 0.00001) for
the addition of apoB given LDL-C.
Taken singly, without any information about LDL particles,
HDL-C was somewhat more informative than the other
HDL-related factor, apoA1 (x
2 ¼ 290.6 and 212.9, respectively:
Table 4). However, part of the negative predictive power of
HDL-C came from its negative association with apoB (Table 3).
Given apoB, the gain from adding HDL-C was reduced and that
from adding apoA1 was increased, so apoA1 became more infor-
mative than HDL-C (x
2 ¼ 278.5 and 187.7, respectively, Table 4).
In the joint relationship of risk to the measurements of apoB,
apoA1, and HDL-C the regression coefﬁcient for HDL-C remained
slightly negative.
The two strongest risk factors were apoB and, given apoB,
apoA1. Moreover, their joint effect was much stronger than that
of either alone [x
2 ¼ 558.2 for their joint ﬁt: Supplementary
material online, Table A8 (279.7þ278.5 in Table 4)]. Measurements
of LDL-C and HDL-C were weaker predictors (x
2= 462.9 for
their joint ﬁt: Supplementary material online, Table A8). ApoB
was positively and apoA1 negatively associated with risk, and the
ratio apoB/apoA1 encapsulated almost all the risk prediction
from these two measurements, or from all four measurements
(Supplementary material online, Table A8). When all four measure-
ments were ﬁtted, the improvement in predictive power over
just apoB and apoA1 was conventionally signiﬁcant, but slight
Figure 2 Effect of age on relative risk per 2SD difference in the usual levels of apolipoproteins and total cholesterol. Relative risks and 95%
conﬁdence intervals (for 3510 cases and 9805 controls) are adjusted for sex, smoking, and body mass index. RR, relative risk; SD, standard
deviation of usual value in cases.
Effects of ApoB, ApoA1, LDL-C, and HDL-C on risk 2141(x
2 ¼ 567.0–558.2¼8.8 on 2 df; P ¼ 0.02: Supplementary material
online, Table A8).
Joint relationship of risk to usual values
The joint relationship of risk with two strongly correlated factors,
such as apoB and LDL-C, cannot be as easily corrected for measure-
ment error
25 as single-factor relationships can be. If, however, both
analytes are expressed comparably, in units of 2SD, then their sum is
approximately uncorrelated with the difference between them.
When risk is related jointly to this sum and difference, the appropri-
ate correction factors for the two terms should therefore
be approximately independent of each other. As the sum (apoB þ
LDL-C) is more reproducible in measurements taken a few years
apart than is the difference (apoB2LDL-C), correction for the
effects of measurement error has less effect on the regression
coefﬁcient for the sum than on that for the difference.
Numerical detail of joint relationship (Supplementary material
online, Panel A1):
The log relative risk (with both analytes in units of 2SD) was:
0:35   measuredðapoB þ LDL-CÞ
þ 0:45   measuredðapoB–LDL-CÞ;
which depends strongly on measured apoB but not on measured
LDL-C. After correction for measurement error, however, this
formula became:
0:5   usual ðapoB þ LDL-CÞþ1:5   usual ðapoB–LDL-CÞ;
which rearranges to:
2:0   usual apoB–1:0   usual LDL-C:
This indicates that, given the usual value of apoB, the usual value
of LDL-C was strongly negatively correlated with risk (regression
coefﬁcient –1.05, SE 0.26, P , 0.0001).
Figure 3 Effects of sex, smoking, and body mass index on relative risk per 2SD difference in the usual levels of apolipoproteins and total
cholesterol. Relative risks, with 95% conﬁdence intervals and x
2 tests for heterogeneity, for 3510 cases and 9805 controls. Analyses of
each factor are adjusted for age and the two other factors. RR, relative risk; SD, standard deviation of usual value in cases; BMI, body mass index.
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Although apoA1, apoB, and LDL-C among cases were approxi-
mately independent of hours from onset of symptoms, HDL-C
increased by about 1% per hour (Supplementary material
online, Figure A1). Despite correcting for this (Supplementary
material online, Appendix), the exact pre-infarction value was
somewhat uncertain. Although reasonable uncertainties in how
to extrapolate HDL-C back to pre-infarction levels have little
effect on the results for HDL-C alone (or for HDL-C given
apoB), they could appreciably affect results for HDL-C given
apoA1, so no analyses of this are presented (beyond those in
Table 4).
In some age/sex groups, cases substantially outnumbered con-
trols, or vice-versa. This has been allowed for by adjustment of
all analyses for age and sex, but similar results were obtained by
random selection of a subset balanced by sex and single year of
age. This and the other sensitivity analyses are in Supplementary
material online, Table A9.
Discussion
As expected, when each of the four main risk factors was con-
sidered separately, usual levels of apoB and LDL-C were both
strongly positively associated with risk, while usual levels of
apoA1 and HDL-C were both strongly negatively associated with
risk. A key additional ﬁnding is that, given the usual apoB, usual
LDL-C was negatively associated with risk.
Causal relevance of low-density
lipoprotein particles
Plasma apoB reﬂects precisely the total number of LDL-related
particles (LDL particles or their triglyceride-rich precursors). As
LDL particles greatly outnumber their precursors, plasma apoB
is closely correlated with the number of LDL particles per unit
volume. Genetic defects that decrease clearance of LDL particles
cause familial hypercholesterolaemia and very high risk, showing
that LDL particles can actually cause coronary artery disease. Like-
wise, statin treatment increases clearance of LDL particles and, in
randomized trials, causes a substantial reduction in apoB, in
LDL-C, and in risk.
26 Hence, the strong association of apoB
with MI risk must to some considerable extent reﬂect the
causal relationship between LDL particles and disease. Our
ﬁnding that, for a given usual apoB, lower LDL-C was associated
with a higher risk of MI supports previous suggestions
27 that, on
average, LDL particles with low cholesterol content per particle
(small, dense LDL particles) are particularly hazardous. Reliable
assessment of the risks caused by particular types of LDL particle
requires, however, more direct measurement of the numbers of
particles of different types and subtypes, allowing their inter-
relationships to be explored.
Causal relevance of high-density
lipoprotein particles
Plasma apoB is not strongly related to apoA1, but it is strongly inver-
sely related to HDL-C. (This is partly because triglyceride-rich LDL
precursors can remove cholesterol from the larger HDL particles,
................................................................................
................................................................................
................................................................................
Table 3 Correlation coefﬁcients (c) between
measurements of different lipid-related factors
Same
sample
(9805)
Different
sample
(2 3 1042)
Within LDL particles
ApoB vs. LDL-C 0.85 0.68
Within HDL particles
ApoA1 vs. HDL-C 0.70 0.64
Between LDL and HDL particles
ApoB vs. apoA1 0.09 20.06
ApoB vs. HDL-C 20.22 20.20
ApoB vs. HDL-C/apoA1 20.39 20.25
LDL-C vs. apoA1 0.06 0.00
LDL-C vs. HDL-C 20.06 20.08
LDL-C vs. HDL-C/apoA1 20.13 20.13
LDL-C/apoB vs. apoA1 20.04 0.11
LDL-C/apoB vs. HDL-C 0.24 0.18
LDL-C/apoB vs. HDL-C/apoA1 0.39 0.17
The standard error of each c, estimated as (1 2 c
2)/
p
N, is ,0.022. Same sample:
all 9805 controls in the present study. Different sample: 1042 controls with
re-measurement 2–3 years later (yielding two independent estimates of each
correlation coefﬁcient; their average is tabulated).
................................................................................
................................................................................
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Table 4 Comparison of predictive strengths for
myocardial infarction relative risk of adding different
combinations of lipid-related terms
Added
lipid-related
terms
Degrees
of
freedom
(df)
Improvement
in ﬁt (x
2)
a
Direction of
association of
respective
terms
LDL related
LDL-C 1 175.2 +
ApoB 1 279.7 +
ApoB, LDL-C 2 281.3 +, 2
HDL related
HDL-C 1 290.6 2
ApoA1 1 212.9 2
ApoA1, HDL-C 2 312.6 2, 2
HDL related, with apoB already in the model
HDL-C 1 187.7 2
ApoA1 1 278.5 2
ApoA1, HDL-C 2 287.2 2, 2
aImprovement in the prediction of relative risk by the addition of the measured
values of various lipid-related terms to the basic model in which relative risk
depends only on age, sex, smoking, and BMI (and, where indicated, the measured
value of apoB). The x
2 value is twice the improvement in the log-likelihood on
addition of extra terms (with df= no. of extra terms).
Effects of ApoB, ApoA1, LDL-C, and HDL-C on risk 2143reducing HDL-C levels but not HDL particle numbers.) To the
extent that adjustment for apoB can allow for the effects of the
LDL-related particles on risk and on the HDL system, the indepen-
dent relevance of the HDL system is best assessed by its relation-
ship with risk given apoB. This was stronger for low apoA1 than
for low HDL-C. These associations of risk with low levels of
HDL-related factors presumably reﬂect a real protective effect of
some type(s) of HDL particle, since the HDL system is, among
other things, responsible for reverse cholesterol transport. The
difference between apoA1 and HDL-C in the strengths of their
independent associations with risk (given apoB) suggests that
some types of HDL particle may be more protective than others.
Unfortunately, however, uncertainty in the extrapolation of post-
infarction HDL-C (and triglyceride) values in cases back to their
pre-infarction values precluded further pursuit of this. Nonetheless,
the strong correlation of apoA1 with low risk provides evidence of a
real protective effect of at least some type(s) of small HDL particle.
Causal relevance of triglyceride-rich
precursors
Triglyceride-rich precursors of LDL particles are important deter-
minants of the plasma levels of particular types of LDL particle and
(as they can remove cholesterol from some HDL particles) of
particular types of HDL particle. Our statistical analyses sought
to elucidate the effects of LDL and HDL particles on disease, so
it was not appropriate to adjust for triglyceride levels, even if
these do correlate with some aspects of the HDL and LDL
system of particles. (Moreover, triglyceride levels change after
the onset of MI, distorting case–control comparisons of them.)
Risk prediction from a single
blood sample
Given the usual values of apoB and apoA1, the usual values of
LDL-C and HDL-C appeared to be informatively related to risk.
Given the measured values of apoB and apoA1, however, the
measured values of LDL-C and HDL-C were only weakly related
to risk, and for risk prediction from a single set of measurements
on a single blood sample what matters is the relevance of the
measured values.
In this study, the ratio apoB/apoA1 encapsulated almost all the
information from measurements of these two lipoproteins and
of both cholesterol fractions (Table 2, Supplementary material
online, Table A8). It was substantially more informative than the
ratio LDL-C/HDL-C, more than twice as informative as either
LDL-C or non-HDL cholesterol (the main biochemical treatment
criteria in various current guidelines
28,29) and about ﬁve times as
informative as total cholesterol.
Routine measurement of apoB, apoA1, and their ratio apoB/
apoA1 is widely practicable, and the present results indicate that
there is about seven-fold variation in the relative risk of MI
between the top and bottom deciles of the measured values of
this ratio in UK heart disease patients (Figure 1). Moreover, the
apoB/apoA1 ratio is informative even in old age (70–79) and is
highly reproducible, with a self-correlation coefﬁcient of 0.81 in
the present study between measurements on samples taken a
few years apart (Table 2). Although the present study was
restricted to the UK, the large INTERHEART case–control
study
30 demonstrated the global importance of a single measure-
ment of this ratio, and reported it to be better than any
cholesterol-based ratios. (We note, however, that time from
onset of symptoms in cases was not corrected for in their
HDL-C analyses.)
If total and HDL cholesterol are the only measurements avail-
able, then our study suggests that risk prediction would be
better based on their ratio than on their difference, non-HDL
cholesterol, which was substantially less predictive of risk. This
was also found in a meta-analysis of prospective studies.
21 In
those studies (none with posted blood samples), a 1.33 lower
usual value of total/HDL cholesterol was associated with relative
risks of 0.56 and 0.60, respectively, for ischaemic heart disease
mortality at ages 40–59 and 60–69 years. In the present study
of non-fatal MI (at a median age of 60 years), the corresponding
relative risk was 0.58, in close agreement.
Case–control designs have inherent limitations, but our ana-
lyses are unaffected by any uncertainties of calibration and have
incorporated appropriate adjustments for the main potential
biases, and for the regression dilution bias. In addition, a range
of sensitivity analyses (Supplementary material online, Table A9)
have conﬁrmed that alternative adjustments make little difference.
Furthermore, the ratio apoB/apoA1 should be little affected by
methodological problems. The conclusion that single measure-
ments of apoB and apoA1 are more predictive than single
measurements of LDL-C and HDL-C is consistent with a recent
review,
7 and is what would be expected if, given the usual apoB
and apoA1, the usual LDL-C is negatively related to risk.
Potential value of further measures
A technique that directly counts particular subtypes of lipoprotein
particles may well be much more informative about risk than just
apoB and apoA1 (which effectively ignore differences between sub-
types of LDL and of HDL particles). Nuclear magnetic resonance
or gradient gel electrophoresis could help provide this, based on
differences in particle size or structure,
4 although there may be
complex inter-relationships between the errors with which differ-
ent subtypes are measured. Such approaches may help identify
more relevant targets for intervention than simply lowering LDL
cholesterol or raising HDL cholesterol.
Conclusion
The strongly positive association of the ratio apoB/apoA1 with the
relative risk of MI in this study, which remains steep even at the
lowest end of the normal range in the UK, should be qualitatively
generalizable to other populations without prior vascular disease
or medication. In patients with prior disease, or taking statins or
other drugs that affect apolipoprotein values and/or recurrence
risks, however, the apparent associations may well be distorted,
and the widespread use of lipid-altering drugs means that studies
nowadays might not be as directly informative. The other main
qualitative conclusions should also be generalizable: different
types of LDL particle differ, perhaps substantially, in their
adverse effects; the evidence of a protective effect is deﬁnite for
at least some subtypes of HDL particles; the total numbers of
S. Parish et al. 2144LDL particles (or, perhaps better, of small LDL particles) and of
HDL particles (or, perhaps better, of particular subtypes of HDL
particles) may well be more informative about risk than the total
amounts of cholesterol being carried by those particles; measure-
ments of apoB and apoA1 are more informative about risk than
measurements of LDL-C and HDL-C; and, at given levels of
apoB and apoA1, HDL-C should not be considered to be an inde-
pendent protective factor. More detailed information about the
numbers of particular subtypes of LDL particle and of HDL
particle, especially in large prospective studies, could well be
even more informative both for risk prediction and, more impor-
tantly, for understanding the mechanisms that underlie that risk.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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Right coronary artery to superior vena cava ﬁstula: imaging with cardiac
catheterization, 320-detector row computed tomography, magnetic
resonance imaging, and transoesophageal echocardiography
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A 63-year-old woman presented with a
12 months history of progressive retro-
sternal chest pain. Symptoms worsened
on exertion but were ultimately relieved
after administration on nitrates, suggesting
typical cardiac-related angina. Physical
examination was unremarkable. Chest
radiography and electrocardiography
revealed no abnormalities. Transthoracic
echocardiography showed a normal-sized
heart and regular ventricular function
without wall motion abnormalities.
Serum cardiac enzymes were in the
normal range.
Conventional coronary angiography
found no atherosclerosis but revealed a
large ﬁstula (Figure 1A and B) arising
from the medial segment of right
coronary artery (RCA). However, the
site of drainage was not deﬁnitely
identiﬁed. Therefore, contrast-enhanced
electrocardiogram-gated 320-detector
row computed tomography (CT) was
performed and clearly demonstrated a
tortuous and markedly dilated proximal
RCA giving rise to a large ﬁstula
(Figure 3A–D) draining into the superior
vena cava (SVC). Electrocardiogram-gated magnetic resonance imaging exhibited vigorous ﬂow of 0.84 L/min and a left-to-right
shunt volume of 1.2:1 (Figure 2A and B). Additional intra-operative multiplane transoesophageal echocardiography also demonstrated
a large ﬁstula of the RCA to the SVC, conﬁrming the CT and magnetic resonance imaging ﬁndings (Figure 4).
On the basis of patient’s symptoms, surgical ligation of the ﬁstula was recommended. Intra-operatively, a large ﬁstula was seen and a
palpable thrill noted (Figure 5). The proximal end of the ﬁstula was dissected near the origin from the RCA, and both the proximal and
the distal part of the ﬁstula were ligated and carefully sutured.
The patient returned to the intensive-care unit, recovered smoothly from surgery, and was doing well 6 months after discharge.
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